Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 1
https://doi.org/10.18008/1816-5095-2020-3S-542-549
Аннотация
Глаукома — главная причина необратимой слепоты в мире. Ингибиторы карбоангидразы (ИКА), применяемые как системно, так и местно, эффективно снижают внутриглазное давление. В отличие от системных ИКА, 2%-ный дорозоламид и 1%-ный бринзоламид, проникая глубоко в ткани глаза, не приводят к системным эффектам, а поэтому эти препараты нашли широкое применение в лечении глаукомы. В обзоре приводится характеристика различных изоформ карбоангидразы, рассмотрены механизмы действия препаратов, направленные на ее блокирование, анализируются результаты различных исследований по эффектам 2%-го дорозоламида и 1%-го бринзоламида, а также их фиксированных комбинаций. Рассмотрены эффекты ИКА как в качестве монотерапии, так и в сочетании с другими антиглаукомными препаратами. Представлен анализ данных о влиянии ИКА на глазной кровоток.
Об авторе
Н. И. Курышева
Медико-биологический университет инноваций и непрерывного образования ФГБУ ГНЦ РФ «Федеральный биофизический центр им. А.И. Бурназяна» Федерального медико-биологического агентства России;
Консультативно-диагностический отдел Центра офтальмологии Федерального медико-биологического агентства, клиническая больница № 86
Россия
Россия
доктор медицинских наук, профессор, заведующая кафедрой, руководитель консультативно‑диагностического отдела
ул. Гамалеи, 15, Москва, 123098, Российская Федерация
Список литературы
1. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta‑analysis. Ophthalmology. 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
2. Sharif N.A. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res. 2018;13(7):1145–1150. DOI: 10.4103/1673‑5374.235017
3. Tomar J.S., Shen J. Characterization of Carbonic Anhydrase In Vivo Using Magnetic Resonance Spectroscopy. Int J Mol Sci. 2020;21(7):2442. DOI: 10.3390/ijms21072442
4. Supuran C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Reviews Drug Discovery. 2008;7(2):168–181. DOI: 10.1038/nrd2467
5. Kinsey V.E. Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eye, its physiologic significance. AMA Arch Ophthalmol. 1953;50(4):401–417. DOI: 10.1001/archopht.1953.00920030409001
6. Carta F., Supuran C.T., Scozzafava A. Novel therapies for glaucoma: a patent review 2007–2011. Expert Opin Ther Pat. 2012;22(1):79–88. DOI: 10.1517/13543776.2012.649006
7. Becker B. The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor, diamox. Am J Ophthalmol. 1955;39(2 Pt 2):177–184. DOI: 10.1016/0002‑9394(55)90022‑2
8. Maren T.H., Jankowska L., Sanyal G., Edelhauser H.F. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983;36(4):457–479. DOI: 10.1016/0014‑4835(83)90041‑6
9. Silver L.H. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open‑angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126(3):400–408. DOI: 10.1016/s0002‑9394(98)00095‑6
10. Maus T.L., Larsson L.I., McLaren J.W., Brubaker R.F. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115(1):45– 49. DOI: 10.1001/archopht.1997.01100150047008
11. Chiaramonte N., Bua S., Ferraroni M., Nocentini A., Bonardi A., Bartolucci G. 2‑Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem. 2018;151:363–375. DOI: 10.1016/j.ejmech.2018.04.002
12. Nocentini A., Gratteri P., Supuran C.T. Phosphorus versus Sulfur: Discovery of Benzenephosphonamidates as Versatile Sulfonamide‑Mimic Chemotypes Acting as Carbonic Anhydrase Inhibitors. Chemistry. 2019;25(5):1188–1192. DOI: 10.1002/chem.201805039
13. Ghorai S., Pulya S., Ghosh K. Structure‑activity relationship of Human Carbonic Anhydrase‑II inhibitors: Detailed Insight for future development as anti‑glaucoma agents. Bioorganic Chemistry. 2019; 95:103557. DOI: 10.1016/j.bioorg.2019.103557
14. Macknight A.D., McLaughlin C.W., Peart D. Formation of the aqueous humor. Clin Exp Pharmacol Physiol. 2000;27(1–2):100–106. DOI: 10.1046/j.1440‑1681.2000.03208.x
15. Sall K. The efficacy and safety of brinzolamide 1 % ophthalmic suspension (Azopt) as a primary therapy in patients with open‑angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S155–S162. DOI: 10.1016/s0039‑6257(99)00107‑1
16. Shin D. Adjunctive therapy with brinzolamide 1 % ophthalmic suspension (Azopt) in patients with open‑angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(Suppl 2):S163–S168. DOI: 10.1016/s0039‑6257(99)00106‑x
17. Michaud J.E., Friren B. Comparison of topical brinzolamide 1 % and dorzolamide 2 % eye drops given twice daily in addition to timolol 0.5 % in patients with primary open‑angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–243. DOI: 10.1016/s0002‑9394(01)00974‑6
18. March W.F., Ochsner K.I. The long‑term safety and efficacy of brinzolamide 1.0 % (azopt) in patients with primary open‑angle glaucoma or ocular hypertension. The Brinzolamide Long‑Term Therapy Study Group. Am J Ophthalmol. 2000;129(2):136–143. DOI: 10.1016/s0002‑9394(99)00343‑8
19. Wang T.H., Huang J.Y., Hung P.T. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc. 2004;103(5):369–373. DOI: 10.29828/JFMA.200405.0008
20. Liu Y., Zhao J., Zhong X., Wei Q., Huang Y. Efficacy and Safety of Brinzolamide as Add‑On to Prostaglandin Analogues or β‑Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta‑Analysis. Front Pharmacol. 2019;10:679. DOI: 10.3389/fphar.2019.00679
21. Konstas A.G.P., Quaranta, L., Bozkurt B., Katsanos A., Garcia‑Feijoo J., Rossetti L. 24‑h Efficacy of glaucoma treatment options. Adv. Ther. 2016;33(4):481–517. DOI: 10.1007/s12325‑016‑0302‑0
22. Hollo G., Chiselita D., Petkova N., Cvenkel B., Liehneova I., Izgi B. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open‑angle glaucoma. Eur. J. Ophthalmol. 2006;16(6):816–823. DOI: 10.5301/EJO.2008.2070
23. Lusthaus J.A., Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension: a safety evaluation. Expert Opin Drug Saf. 2017;16(9):1071–1078. DOI: 10.1080/14740338.2017.1346083
24. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119–S129. DOI: 10.1016/s0039‑6257(99)00108‑3
25. Shoji N. Brinzolamide: efficacy, safety and its role in the management of glaucoma. Expert Rev Ophthalmol. 2007;2:695–704.
26. Strahlman E., Tipping R., Vogel R. A double‑masked, randomized 1‑year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113(8):1009–1016. DOI: 10.1001/archopht.1995.01100080061030
27. Hoyng P.F., van Beek L.M. Pharmacological therapy for glaucoma: A review. Drugs. 2000;59(3):411–434. DOI: 10.2165/00003495‑200059030‑00003
28. Arici M.K., Topalkara A. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22:37–42. DOI: 10.1023/a:1006176713983
29. Ott E., Mills M., Arango S. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch. Ophthalmol. 2005; 123(9):1177–1186. DOI: 10.1001/archopht.123.9.1177
30. Miglior S., Zeyen Th., Pfeiffer N. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112(3):366–375. DOI: 10.1016/j.ophtha.2004.11.030
31. Henderer J.D., Wilson R.P., Moster M.R. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. J Glaucoma. 2005;14(4):267–270. DOI: 10.1016/j.ajo.2005.10.033
32. Boyle J.E., Ghosh K., Gieser D.K. A randomized trial comparing the dorzolamidetimolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1998;105(10):1945–1951. DOI: 10.1016/s0161‑6420(98)91046‑6
33. Francis B.A., Du L.T., Berke S. Comparing the fixed combination dorzolamidetimolol (Cosopt) to concomitant administration of 2 % dorzolamide (Trusopt) and 0.5 % timolol — a randomized controlled trial and replacement study. J Clin Pharm Ther, 2004;29(4):375–380. DOI: 10.1111/j.1365‑2710.2004.00574.x
34. Clineschmidt C.M., Williams R.D., Snyder E. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide‑timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology. 1998;105(10):1952–1959. DOI: 10.1016/s0161‑6420(98)91047‑8
35. Solish A., DeLucca P., Cassel D. Dorzolamide/timolol fixed com‑ bination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure. J Glaucoma. 2004;13(2):149–157. DOI: 10.1097/00061198‑200404000‑00012
36. Honrubia F.M., Larsson L.I., Spiegel D. A comparison of the effects of intraocular pressure of latanoprost 0.005 % and the fixed combination of dorzolamide 2 % and timolol 0.5 % in patients with open‑angle glaucoma. Acta Ophthalmol Scand, 2002;80:635–641.
37. Fechtner R.D., Airaksinen P.J., Getson A.J. Efficacy and tolerability of the dorzolamide 2 % / timolol 0.5 % combination (COSOPT) versus latanoprost 0.005 % (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82(1):42–48. DOI: 10.1046/j.1600‑0420.2004.0205.x
38. Martinez A., Sanchez M. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr Med Res Opin. 2007;23(3):595–599.
39. Januleviciene I., Harris A., Kagemann L. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open‑ angle glaucoma patients. Acta Ophthalmol Scand. 2004;82(6):730–737. DOI: 10.1111/j.1600‑0420.2004.00358.x
40. Konstas A.G.P., Papapanos P., Tersis I. Twenty‑four hour diurnal curve comparison of commercially available latanoprost 0.005 % versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110(7):1357–1360.
41. Day D.G., Sharpe E.D., Beischel C.J. Safety and efficacy of bimatoprost 0.03 % versus timolol maleate 0.5 % / dorzolamide 2 % fixed combination. Eur J Ophthalmol, 2005;15(3):336–342. DOI: 10.1177/112067210501500304
42. Caca I., Simsek H., Unlu K. A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open‑angle glaucoma. Ann Ophthalmol (Skokie). 2006;38(2):111–115. DOI: 10.1385/AO:38:2:111
43. Coleman A., Lerner F., Bernstein P. A 3‑month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003;110(12):2362–2368. DOI: 10.1016/S0161‑6420(03)00662‑6
44. Zabriskie N., Netland P. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double‑masked, parallel clinical trials. Adv Ther. 2003;20(2):92–100.
45. Konstas A.G., Kozobolis V.P., Lallos N. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005 % / timolol maleate 0.5 % and dorzolamide 2 % / timolol maleate 0.5 %. Eye. 2004;18(12):1264–1269. DOI: 10.1038/sj.eye.6701446
46. Shin D.H., Feldman R.M., Sheu W. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111(2):276–282. DOI: 10.1016/j.ophtha.2003.05.019
47. Barnebey H., Kwok S.Y. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204–1212. DOI: 10.1016/s0149‑2918(00)83063‑5
48. Silver L.H., Brinzolamide Comfort Study Group. Ocular comfort of brinzolamide 1.0 % ophthalmic suspension compared with dorzolamide 2.0 % ophthalmic solution. Results from two multicenter comfort studies. Surv Ophthalmol. 2000;44(Suppl 2):S141–S145. DOI: 10.1016/s0039‑6257(99)00111‑3
49. Aguayo Bonniard A., Yeung J.Y., Chan C.C., Birt C.M. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279–1289. DOI: 10.1080/17425255.2016.1209481
50. Jaenen N., Baudouin C., Pouliquen P. Ocular symptoms and signs with preserved and preservative‑free glaucoma medications. European Journal of Ophthalmology. 2007;17(3):341–349.
51. Thygesen J. Glaucoma therapy: preservative‑free for all? Clinical Ophthalmology. 2018;12:707–717. DOI: 10.2147/OPTH.S150816
52. Shedden А., Adamsons I., Getson A. Comparison of the efficacy and tolerability of preservative‑free and preservative‑containing formulations of the dorzolamide/timolol fixed combination (COSOPTTM) in patients with elevated intraocular pressure in a randomized clinical trialю Graefes Arch Clin Exp Ophthalmol. 2010;248:1757–1764. DOI: 10.1007/s00417‑010‑1397‑7
53. Chandra S., Muir E.R., Deo K., Kiel J.W., Duong T.Q. Effects of dorzolamide on retinal and choroidal blood flow in the DBA/2J mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57:826–831. DOI: 10.1167/ iovs.15‑18291
54. Dong Y.R., Huang S.W., Cui, J.Z., Yoshitomi T. Effects of brinzolamide on rabbit ocular blood flow in vivo and ex vivo. Int. J. Ophthalmol. 2018;11(5):719–725. DOI: 10.18240/ijo.2018.05.03
55. Laux B.E., Raichle M.E. The effect of acetazolamide on cerebral blood flow and oxygen utilization in the rhesus monkey. J Clin Invest. 1978;62:585–592. DOI: 10.1172/JCI109164
56. Petropoulos I.K., Pournaras J.A., Munoz J.L. Effect of acetazolamide on the optic disc oxygenation in miniature pigs. Klin Monatsbl Augenheilkd. 2004;221(5):367–370. DOI: 10.1055/S‑2004‑812816
57. Reber F., Gersch U., Funk R.W. Blockers of carbonic anhydrase can cause increase of retinal capillary diameter, decrease of extracellular and increase of intracellular pH in rat retinal organ culture. Graefes Arch Clin Exp Ophthalmol. 2003;241(2):140–148. DOI: 10.1007/s00417‑002‑0560‑1
58. Dallinger S., Bobr B., Findl O. Effects of acetazolamide on choroidal blood flow. Stroke. 1998;29:997–1001. DOI: 10.1161/01.STR.29.5.997
59. Harris A., Tippke S., Sievers C. Acetazolamide and CO2: acute effects on cerebral and retrobulbar hemodynamics. J Glaucoma. 1996;5(1):39–45. DOI: 10.1097/00061198‑199602000‑00007
60. Wilson T.M., Strang R., MacKenzie E.T. The response of the choroidal and cerebral circulations to changing arterial PCO2 and acetazolamide in the baboon. Invest Ophthalmol Vis Sci. 1977;16:576–580.
61. Bill A. Effects of acetazolamide and carotid occlusion on the ocular blood flow in unanesthetized rabbits. Invest Ophthalmol. 1974;13:954–958.
62. Grunwald J.E., Zinn H. The acute effect of oral acetazolamide on macular blood flow. Invest Ophthalmol Vis Sci. 1992;33(3):504–507.
63. Kerty E., Hørven I., Dahl A. Ocular and cerebral blood flow measurements in healthy subjects. A comparison of blood flow velocity and dynamic tonometry measurements before and after acetazolamide. Acta Ophthalmol (Copenh). 1994;72(4):401–408. DOI: 10.1111/j.1755‑3768.1994.tb02786.x
64. Sugrue M.F., Harris A., Adamsons I. Dorzolamide hydrochloride: a topically active, carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today. 1997;33:283–298.
65. Schmitz K., Banditt P., Motschmann M. Population pharmacokinetics of 2 % topical dorzolamide in the aqueous humor of humans. Invest Ophthalmol Vis Sci. 1999;40:1621–1624.
66. Butt Z., McKillop G., O’Brien C. Measurement of ocular blood flow velocity using colour Doppler imaging in low tension glaucoma. Eye. 1995;9:29–33. DOI: 10.1038/eye.1995.4
67. Martinez A., Sanchez M. A comparison of the effects of 0.005 % latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr Med Res Opin. 2006;22(1):67–73. DOI: 10.1185/030079906X80215
68. Siesky B., Harris A., Sines D. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open‑angle glaucoma. J Ocul Pharmacol Ther. 2006;22:353–361. DOI: 10.1089/JOP.2006.22.353
69. Курышева Н.И., Апостолова А.С., Киселева Т.Н. Бринзоламид/тимолол и латанопрост в лечении псевдоэксфолиативной глаукомы. Национальный журнал глаукома. 2014,3:52–63.
70. Iester M., Altieri M., Michelson G. Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 2003;218(6):390–396. DOI: 10.1159/000080942
71. Arend O., Harris A., Wolter P. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open‑angle glaucoma patients. Acta Ophthalmol Scand. 2003;81:474–479. DOI: 10.1034/J.1600‑0420.2003.00122.X
72. Harris A., Arend O., Kagemann L. Dorzolamide, visual function and ocular hemodynamics in normal‑tension glaucoma. J Ocul Pharmacol Ther. 1999;15(3):189–197. DOI: 10.1089/jop.1999.15.189
73. Bergstrand I.C., Heijl A., Harris A. Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double‑masked study. Acta Ophthalmol Scand. 2002;80(2):176–182.
74. Siesky B., Harris A., Edward Brizendine E. Literature Review and Meta‑Analysis of Topica l Carbonic Anhydrase Inhibitors and Ocular Blood Flow. Survey of Ophthalmology. 2009;54(1):33–46. DOI: 10.1016/j.survophthal.2008.06.002
75. Fuchsja ger ̈ ‑Mayrl G., Wally B., Rainer G. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293–1297. DOI: 10.1136/bjo.2005.067637
76. Sugrue M.F., Mallogra P., Schwam H. A comparison of two topically effective ocular hypotensive carbonic anhydrase inhibitors in experimental animals. Curr Eye Res. 1990;9(6):607–615. DOI: 10.3109/02713689008999600
77. Rolle T., Tofani F., Brogliatti B., Grignolo F.M. The effects of dorzolamide 2 % and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open‑angle glaucoma patients. Eye. 2008;22(9):1172–1179. DOI: 10.1038/sj.eye.6703071
78. Harris A., Arend O., Chung H.S. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal‑tension glaucoma patients. Ophthalmology. 2000;107(3):430–434. DOI: 10.1016/s0161‑6420(99)00093‑7
79. Marinez A., Sanchez M. Effects of dorzolamide 2 % added to timolol maleate 0.5 % on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open‑angle glaucoma: A single‑center 4‑year, open‑label study. Clin Ther. 2008;30(6):1120–1134.
80. Kurysheva N., Maslova E.V., Zolnikova I.V., Fomin A.V. A comparative study of structural, functional and circulatory parameters in glaucoma diagnostics. PLoS ONE. 2018;13(8):e0201599. DOI: 10.1371/journal.pone.0201599
Рецензия
Для цитирования:
Курышева Н.И. Ингибиторы карбоангидразы в лечении глаукомы. Обзор. Часть 1. Офтальмология. 2020;17(3s):542-549. https://doi.org/10.18008/1816-5095-2020-3S-542-549
For citation:
Kurysheva N.I. Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part I. Ophthalmology in Russia. 2020;17(3s):542-549. (In Russ.) https://doi.org/10.18008/1816-5095-2020-3S-542-549
Просмотров: 3314
Послать статью по эл. почте 